Table 7.

Logistic regression analysis of miR-20a-5p expression levels in nucleus, in relation to clinicopathological parameters and breast cancer risk factors.

	N	Odds ratio	95% Confidence interval	p-value
Tumor size	312	0.81	0.67–0.99	0.039
Tumor grade
1	98	Ref	Ref	Ref
2	132	0.65	0.38–1.11	0.12
3	81	1.14	0.62–2.09	0.68
Molecular subgroup
Luminal A	193	Ref	Ref	Ref
Luminal B	63	0.94	0.53–1.68	0.84
HER2-enriched	15	0.47	0.16–1.38	0.17
Basal like	40	1.06	0.53–2.13	0.87
Estrogen receptor
Negative	60	Ref	Ref	Ref
Positive	252	1.25	0.71–2.19	0.45
Progesterone receptor
Negative	100	Ref	Ref	Ref
Positive	202	1.15	0.71–1.86	0.57
HER2
Negative	273	Ref	Ref	Ref
Positive	38	0.80	0.40–1.57	0.51
Ki67
Low	175	Ref	Ref	Ref
High	87	1.57	0.92–2.69	0.10
Lymph node metastasis
No	216	Ref	Ref	Ref
Yes	94	0.60	0.37–0.97	0.039
Distant metastasisa
No	275	Ref	Ref	Ref
Yes	34	0.62	0.30–1.27	0.19
Relapse
No	285	Ref	Ref	Ref
Yes	25	1.98	0.80–4.89	0.14
Menopausal statusb
Post	219	Ref	Ref	Ref
Pre	93	1.60	0.97–2.65	0.07
BMI
Low	276	Ref	Ref	Ref
High	29	0.75	0.35–1.62	0.47
Parity
Nulliparous	32	Ref	Ref	Ref
Parous	280	0.80	0.38–1.70	0.56
Oral contraceptives
Never	115	Ref	Ref	Ref
Ever	186	1.18	0.74–1.89	0.49
Alcohol	306	0.99	0.94–1.04	0.72
Smoking
Never	108	Ref	Ref	Ref
Ever	203	0.86	0.54–1.39	0.55

HER2 Human epidermal growth factor receptor 2. ^aAt any time, ^bAt diagnosis.